BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Dr. Reddys Laboratories Ltd. has announced that they have settled the ongoing Revlimid (lenalidomide) litigation with Bristol Myers Squibb.
The settlement gives Dr. Reddy a license to sell limited volumes of gRevlimid from an undisclosed date which is post March 2022 ( post settlement date with Natco Pharma Ltd.).
The details on volume and exact timelines are not disclosed.
There are now three players – Natco Pharma, Dr. Reddy and Alvogen which have entered into a settlement agreement with the innovator.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR